article
A new approach to Organ-on-a-Chip
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
whitepaper
Tech note: Practical tips for cellular quantification and imaging using Thermo Scientific Varioskan LUX multimode reader and Invitrogen EVOS FL Auto Cell Imaging System
This technical note offers practical tips for facilitating the use of Thermo ScientificTM VarioskanTM LUX multimode reader and InvitrogenTM EVOSTM FL Auto Cell Imaging System with the goal of achieving successful cellular quantification and imaging of mammalian cells in microplate-based assays...
news
Nimbus Therapeutics enters into strategic partnership with Charles River Laboratories to advance new therapeutic programs
Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.
news
Charles River Laboratories announces launch of triple-immunodeficient mouse model for oncology research
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model...
webinar
Novel readouts for neuropathic pain models
3 April 2017 | By Charles River
This webinar reviews standard neuropathic pain models and readouts and will include fine motor kinematic analysis to highlight gait changes...
news
Essen BioScience launches the IncuCyte® S3 live-cell analysis platform
Enables real-time measurements of cell health, proliferation, movement and function while cells remain unperturbed in a physiologically relevant environment...
news
IntelliCyt launches novel assay system to accelerate cell line development
The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals...
article
Fast-tracking the approach to drug discovery and development
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
whitepaper
Brochure: Custom Assay Development
The Custom Assay Development (CAD) program at DiscoverX develops tailor-made cell lines optimised for your needs, enabling you to jump start your drug discovery programs...
article
Assays In-Depth Focus 2017
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
article
Whole animal screening: back to the future
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
article
Product Hub: Flow cytometric screening assays in drug discovery
Flow cytometry is a laser-based technology – a powerful tool for drug discovery and the screening process and can be used in all settings, including research, clinical, pharmaceutical and biotechnology. The increasing capabilities of flow cytometers make their incorporation into drug development and screening optimal...
webinar
Vertical integration of CRISPR/Cas9 in drug discovery
10 February 2017 | By Charles River
In this webinar, Charles River discuss the utilisation of CRISPR/Cas9 technology in drug discovery, with an emphasis on generation of in vitro models for high-throughput screening, and creating new mouse models...
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
Update on Charles River’s collaboration with Moderna Therapeutics
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
